
|Videos|October 28, 2022
Dr. Kapur on patient preferences for OAB third-line therapies
Author(s)Urology Times staff
“With this study, we gained a better understanding of the features of third line therapy for overactive bladder, that patients find favorable and unfavorable,” says Anjali Kapur, MD.
Advertisement
In this video, Anjali Kapur, MD, shares the take-home message of the recent Neurourology and Urodynamics paper, “An analysis of factors that influence patient preference of third-line therapy for overactive bladder.” Kapur is a urology resident at Renaissance School of Medicine at Stony Brook University, Stony Brook, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Individualizing androgen pathway therapy in mCSPC
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












